XORTX Therapeutics shares surge 30.59% premarket after 180-day Nasdaq compliance extension and acquisition of renal anti-fibrotic therapeutic program.

XORTX Therapeutics surged 30.59% in premarket trading following the announcement of acquiring a renal anti-fibrotic therapeutic program from Vectus Biosystems and closing a $1.1 million registered direct offering. The company also highlighted pioneering genome-wide research on gout pathogenic pathways, reinforcing its corporate progress in advancing therapeutic innovations. These developments signal expanded pipeline potential and capital infusion, aligning with the stock’s sharp premarket gain.